Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of IPHA is 5.2 and suggests 215% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell